Extracted from this filing and checked against the source text.
Earnings Releases
SEC 8-K Item 2.02
confidence 0.95
HARVARD BIOSCIENCE INC reported the fourth quarter ended December 31, 2023 results: revenue $28.2 million, net income $(1.8) million, EPS $(0.04) per diluted share.
- Period
- the fourth quarter ended December 31, 2023
- Revenue
- $28.2 million
- Net income
- $(1.8) million
- EPS
- $(0.04) per diluted share
- Result
- reported results
Exact text from the filing
a filing. --- EX-99.1 (EXHIBIT 99.1) --- EX-99.1 2 exh_991.htm EXHIBIT 99.1 Exhibit 99.1 Harvard Bioscience Announces Fourth Quarter 2023 Financial Results · Q4 Revenues of $28.2 million · Q4 Gross Margin of 58.0% (230 bps year-over-year improvement) · Q4 operating income of $0.3 million, adjusted operating income of $3.3 million · Strong operating cash flow
View on SEC.gov
Earnings Releases
SEC 8-K Item 2.02
confidence 0.95
HARVARD BIOSCIENCE INC reported the fiscal year ended December 31, 2023 results: revenue $112.3 million, net income $(3.4) million, EPS $(0.08) per diluted share. Guidance initiated.
- Period
- the fiscal year ended December 31, 2023
- Revenue
- $112.3 million
- Net income
- $(3.4) million
- EPS
- $(0.08) per diluted share
- Guidance
- initiated
- Result
- reported results
Exact text from the filing
in the same period last year. Debt was reduced by $2.3 million during the quarter. Year Ended December 31, 2023 Highlights For the year ended December 31, 2023, revenues were $112.3 million, compared to $113.3 million in the same period a year ago. Revenues for the year include a net reduction of $5.0 million from discontinued products compared to 2022. Gross margin
View on SEC.gov